Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Race Oncology Ltd. ( (AU:RAC) ).
Race Oncology Ltd presented promising preclinical data at the European Society for Medical Oncology Congress 2025, showcasing the dual anticancer and cardioprotective benefits of (E,E)-bisantrene when combined with doxorubicin. This data supports their ongoing Phase 1 trial of RC220 in advanced solid tumor patients, highlighting the potential of this combination to enhance anticancer activity while mitigating cardiotoxicity, positioning Race Oncology as a significant player in innovative cancer treatment solutions.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company focused on cancer care. Its lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that inhibits the cancer growth regulator MYC. The company is advancing a proprietary formulation, RC220, to address unmet needs in oncology, particularly in combination with anthracycline doxorubicin for enhanced anticancer activity and cardioprotection. Race Oncology collaborates with various institutions and is exploring partnerships to expand access to RC220 globally.
Average Trading Volume: 441,146
Technical Sentiment Signal: Buy
Current Market Cap: A$748.6M
See more data about RAC stock on TipRanks’ Stock Analysis page.